Combining anticholinergic and anti-inflammatory activities into a single moiety: A novel approach to reduce gastrointestinal toxicity of ibuprofen and ketoprofen

Chemical Biology and Drug Design

Volumn 70, Issue 5, 2007, Pages 450-455

  Halen, Parmeshwari K ^a   Chagti, Kewal K ^a   Giridhar, Rajani ^a   Yadav, Mange R ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Anti inflammatory; Gastrointestinal irritation; Rat paw edema; Ulcerogenicity

Indexed keywords

2 (1 PIPERIDINO)ETHYL 2 (3 BENZOYLPHENYL)PROPIONATE; 2 (1 PIPERIDINO)ETHYL 2 (4 ISOBUTYLPHENYL)PROPIONATE; 2 (1 PYRROLIDINO)ETHYL 2 (3 BENZOYLPHENYL)PROPIONATE; 2 (1 PYRROLIDINO)ETHYL 2 (4 ISOBUTYLPHENYL)PROPIONATE; 2 (4 MORPHOLINO)ETHYL 2 (4 ISOBUTYLPHENYL)PROPIONATE; 2 (4 MORPHOLINOETHYL) 2 (3 BENZOYLPHENYL)PROPIONATE; 2 DIETHYLAMINOETHYL 2 (3 BENZOYLPHENYL)PROPIONATE; 2 DIETHYLAMINOETHYL 2 (4 ISOBUTYLPHENYL)PROPIONATE; 2 DIMETHYLAMINOETHYL 2 (3 BENZOYLPHENYL)PROPIONATE; 2 DIMETHYLAMINOETHYL 2 (4 ISOBUTYLPHENYL)PROPIONATE; 8 METHYL 8 AZABICYCLO[3,2,1]OCTAN 3 YL 2 (3 BENZOYLPHENYL)PROPIONATE; 8 METHYL 8 AZABICYCLO[3.2.1]OCTAN 3 YL 2 (4 ISOBUTYLPHENYL)PROPIONATE; ATROPINE; IBUPROFEN; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG; TROPINOL; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HUMAN; HYDROLYSIS; LONG TERM CARE; PRIORITY JOURNAL; STOMACH SECRETION; ULCEROGENESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINERGIC ANTAGONISTS; DRUG DESIGN; ESTERS; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IBUPROFEN; KETOPROFEN; MALE; MODELS, ANIMAL; PEPTIC ULCER; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 35348943327     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00574.x     Document Type: Article

References (21)

1. Paul A.D., Shah E., Richard M.M., Peter J. (2004) Lessons from the withdrawal of Rofecoxib. Br Med J 329: 867 868.
2. Williams D., Singh M., Hind C. (2006) The effect of the withdrawal of Rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol 62: 366 368.
3. Peter J., Paul A.D. (2004) Older people should not be prescribed "coxibs" in place of conventional NSAIDs. Age Ageing 33: 100 104.
4. Gyires K. (1994) Some of the factors that may mediate or modify the gastrointestinal mucosal damage induced by non-steroidal anti-inflammatory drugs. Inflamm Res 41: 71 79.
5. Yanagawa A., Fukumara T., Matsui H., Uemera H., Endo T., Nakagava T., Mizushima Y. (1992) Possible mechanisms of gastroduodenal mucosal damage in volunteers treated with Non-steroidal antiinflammatory drugs: the usefulness of prodrugs. J Rheumatol 19: 1075 1082.
6. Clarke D.L., Thomson S.R. (2002) Attenuated gastric mucosal blood flow predicts non-healing of benign gastric ulcers. Eur Surg Res 34: 432 436.
7. Bonina F., Trombetta A.B., Pasquae A., De Saija A. (1997) 1-Ethylazacycloalkan-2-one indomethacin esters as new oral prodrugs: chemical stability, enzymatic hydrolysis, anti-inflammatory activity and gastrointestinal toxicity. Int J Pharm 156: 245 250.
8. Venti C., Young J.M., Maloney P.J., McGreevy K. (1989) Synthesis and biological evaluation of ω-(N,N,N-trialkylammonium)alkyl esters and thioesters of carboxylic acid nonsteroidal antiinflammatory agents. Pharma Res 6: 867 873.
9. Mahfouz N.M., Omar F.A., Aboul-Fadl T. (1999) Cyclic amide derivatives as potential prodrugs II: N-hydroxymethyl succinimde-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur J Med Chem 34: 551 562.
10. Cocolas G.H., Cutler S.J. (2004) Cholinergic drugs and related agents. In: Block J.H., Beale J.M., editors. Organic, Medicinal and Pharmaceutical Chemistry. Philadelphia: Lippincott Williams and Wilkins Press p. 579 581.
11. Halen P.K., Chagti K.K., Giridhar R., Yadav M.R. (2006) Synthesis and pharmacological evaluation of some dual-acting aminoalcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity. Chem Biodivers 3: 1238 1247.
12. Halen P.K., Raval M.K., Chagti K.K., Giridhar R., Yadav M.R. (2007) Synthesis and evaluation of some gastrointestinal sparing anti-inflammatory aminoethyl ester derivatives of naphthalene-based NSAIDs. Arch Pharm Chem Life Sci 340: 88 94.
13. Halen P.K., Yadav M.R., Chagti K.K., Reshmi C.S., Giridhar R. (2006) Synthesis and evaluation of dual acting esters of aspirin and ketorolac. Ars Pharm 47: 61 79.
14. Yadav M.R., Halen P.K., Chagti K.K., Hemalata B., Giridhar R. (2005) A novel approach towards therapeutic optimization of diclofenac. Ars Pharm 46: 263 277.
15. Van Rossum J.M., Hurkmans J.H., Walters C.J. (1965) Cumulative dose response curves. J Arch Int Pharmacodyn Ther 143: 299 301.
16. Winter C.A., Risley E.A., Nuss G.W. (1962) Carrageenan-induced edema in hind paw of the rat as an assay. Proc Soc Exp Biol Med 111: 544 547.
17. Parmar N.S., Desai J.K. (1993) A review of the current methodology for the evaluation of gastric and duodenal anti-ulcer agents. Indian J Pharmacol 25: 120 126.
18. Wallace J.L., Cirino G. (1994) The development of gastrointestinal- sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 15: 405 406.
19. Kalgutkar A.S., Crews B.C., Slaeh S., Prudhomme D., Marnett L.J. (2005) Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bio Med Chem 13: 6810 6814.
20. Khanna S., Madan M., Vangoori A., Banerjee R., Thaimattam R., Jafar Sadik Basha S.K., Mullangi R., Casturi S.R., Pal M. (2006) Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors. Bio Med Chem 14: 4820 4826.
21. Kauffman G.L., Aures D. (1980) Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs. Am J Physiol 234: 131 134.